EUVIMEDEUVIMED entdecken
Crossref

Synthesis of 1,2,3‐Triazole and Isoxazole Derivatives of [1,2,4]Triazolo[3,4‐b][1,3,4]thiadiazine as Potent EGFR Targeting Antilung Cancer Agents

Arvapalli Kiran Kumar, T Madhukar Reddy, Sridhar Kavela, Sirassu Narsimha iD, Kavitha Siddoju

Chemistry & Biodiversity · 2026

DOI: 10.1002/cbdv.202502795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Arvapalli Kiran Kumar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Chaitanya (Deemed to Be University), Hyderabad, India. Hauptthemen laut MEDLINE: Triazoles, Antineoplastic Agents, Isoxazoles, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Imidazole‐1,2,4triazolo[3,4‐b][1,3,4]thiadiazines associated 1,2,3‐triazole and isoxazole hybrids were designed and synthesized using a pharmacophore‐hybridization approach that incorporates physiologically active scaffolds. In vitro anticancer activity of the synthesized compounds was screened against two lung cancer cell lines, A‐549 and NCI‐H460, and results revealed that compounds 6d and 6h had substantial efficacy compared to the standard erlotinib. Furthermore, compound 6h (IC 50 = 0.61 ± 0.12 µM) exhibited greater effectiveness as compared to the conventional Erlotinib (IC 50 = 0.64 ± 0.23 µM) in vitro, as shown by EGFR inhibitory tests, whereas compound 6d (IC 50 = 0.65 ± 0.09 µM) indicated notable EGFR inhibitory action. To confirm the activity findings, five potent compounds underwent in silico molecular docking studies, with all compounds demonstrating superior binding energies relative to the standard.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesAntineoplastic AgentsIsoxazolesProtein Kinase InhibitorsThiadiazinesHumansErbB ReceptorsMolecular Docking SimulationStructure-Activity RelationshipDrug Screening Assays, AntitumorCell Line, TumorCell ProliferationMolecular StructureDose-Response Relationship, Drug

Stichwörter der Autor:innen

EGFRdocking studiesisoxazolelung cancerthiadiazinestriazole

Substanzen

TriazolesErbB ReceptorsAntineoplastic AgentsIsoxazolesProtein Kinase InhibitorsThiadiazinesEGFR protein, human

Autor:innen und Institutionen

  • Department of Chemistry, Chaitanya (Deemed to Be University), Hyderabad, India.
  • Department of Physical Sciences/Chemistry, Kakatiya Institute of Technology & Science (Autonomous), Warangal, India.
  • Department of Biotechnology, Chaitanya (Deemed to Be University), Hyderabad, India.

ORCID-Profile: Sirassu Narsimha

Zitieren

APA

Kumar, A. K., Reddy, T. M., Kavela, S., Narsimha, S., & Siddoju, K. (2026). Synthesis of 1,2,3‐Triazole and Isoxazole Derivatives of [1,2,4]Triazolo[3,4‐b][1,3,4]thiadiazine as Potent EGFR Targeting Antilung Cancer Agents. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202502795

Vancouver

Kumar AK, Reddy TM, Kavela S, Narsimha S, Siddoju K. Synthesis of 1,2,3‐Triazole and Isoxazole Derivatives of [1,2,4]Triazolo[3,4‐b][1,3,4]thiadiazine as Potent EGFR Targeting Antilung Cancer Agents. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.202502795

BibTeX
@article{Kumar2026,
  author = {Kumar, Arvapalli Kiran and Reddy, T Madhukar and Kavela, Sridhar and Narsimha, Sirassu and Siddoju, Kavitha},
  title = {Synthesis of 1,2,3‐Triazole and Isoxazole Derivatives of [1,2,4]Triazolo[3,4‐b][1,3,4]thiadiazine as Potent EGFR Targeting Antilung Cancer Agents},
  journal = {Chemistry & Biodiversity},
  year = {2026},
  doi = {10.1002/cbdv.202502795}
}
Kostenlos starten →